Thus, we tested the efficacy of combination treatment with a chemical inhibitor of S100A9 or CXCL12 and αPD1 in BRCA1-MT mice, and found the treatment significantly inhibited mammary tumor growth, recurrence, and metastasis. Here, CXCL12 is linked to breast cancer.